Could two shots be enough? new study tests shorter HPV vaccine for women up to 45
NCT ID NCT04206813
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study looks at whether a 2-dose HPV vaccine (Gardasil 9) works as well as the standard 3-dose schedule in women aged 16 to 45. About 352 women at Boston Medical Center will receive the 2-dose regimen, and researchers will measure their immune response over 6 months. The goal is to see if fewer doses can still provide strong protection against HPV, which causes certain cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
Conditions
Explore the condition pages connected to this study.